

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 - 16 (Canceled).

17. (Currently amended) A method of treating ~~a condition resulting in~~ bone loss, which comprises administering an IL-1 inhibitor, a TNF- α inhibitor, and an OPG protein, wherein “OPG protein” refers to ~~an antibody to OPG ligand or~~ a polypeptide comprising conserved residues from residues 22 to 185 of SEQ ID NOS: 121, 123, and 125.
18. (Original). The method of Claim 17, wherein the TNF- α inhibitor comprises sTNFR-I, sTNFR-II, sTNFR fragments, or sTNFR-Fc, wherein “sTNFR” refers to sTNFR-I or sTNFR-II.
19. (Currently amended) The method of Claim 17, wherein the $\text{TNF-}\alpha[[\square]]$ inhibitor comprises sTNFR-I, sTNFR-II, sTNFR fragments, or sTNFR-Fc, wherein “sTNFR” refers to sTNFR-I or sTNFR-II.
20. (Currently amended). The method of claim 17, wherein the $\text{TNF-}\alpha[[\text{TNF}\alpha]]$ inhibitor comprises 30 kD PEG-sTNFR-I.
21. (Previously presented). The method of claim 18, wherein the sTNFR fragment is a 2.6 kD sTNFR-I fragment.
22. (Previously presented). The method of claim 21, wherein the sTNFR-I fragment comprises 30 kD PEG.
23. (Original). The method of claim 17, wherein the TNF α inhibitor comprises sTNFR-II linked to an Fc region.

24. (Currently amended). The method of claim 17, wherein the TNF- α [[TNF α]] inhibitor is etanercept.

25. (Original). The method of Claim 17, wherein the OPG protein is OPG-Fc.

Claim 26-38 (Canceled).

39. (Currently amended) The method of any of claims 17 to 25, wherein the bone loss results from condition treated is rheumatoid arthritis.

40. (Currently amended) The method of any of claims 17 to 25, wherein the bone loss results from condition treated is multiple sclerosis.

41. (Currently amended) The method of any of claims 17 to 25, wherein the bone loss results from condition treated is osteoporosis.

42. (Currently amended) The method of any of claims 17 to 25, wherein the bone loss results from condition treated is osteomyelitis.

Claim 43 - 61 (Canceled).

62. (Previously presented) The method of Claim 17, wherein the OPG protein comprises a sequence comprising the conserved residues from residues 22 to 185 of SEQ ID NOS: 171, 172, and 173.

63. (Previously presented) The method of Claim 17, wherein the OPG protein comprises residues 22 to 185 of SEQ ID NO: 123.

64. (Previously presented) The method of Claim 17, wherein the OPG protein comprises residues 22 to 185 of SEQ ID NO: 125.

65. (Canceled).

66. (Canceled).